Last update Aug. 6, 2017
Usually used alone or in combination with sofosbuvir in the treatment of hepatitis C.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (high molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk, so that, although there is disagreement (Thompson 2016), some authors consider that treatment with Daclatasvir, alone or in combination with sofosbuvir is not contraindicated during breastfeeding (Spera 2016, LactMed 2016).
We do not have alternatives for C40H50N8O6 .
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.